Clinical trial
Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
NCT00485368 · Bayside Health, Other · Completed
Key facts
| NCT number | NCT00485368 |
|---|---|
| Title | Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome |
| Official title | The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. |
| Lead sponsor | Bayside Health, Other |
| Collaborators | Baker Heart Research Institute The Alfred |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Marfan Syndrome |
| Intervention type | Drug |
| Interventions | Coversyl (perindopril) |
| Enrollment | 17 |
| Start date | Jan 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 13, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: